Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia

Retina

Volumn 29, Issue 8, 2009, Pages 1062-1066

  Cohen, Salomon Y ^a,b  

^a Centre Ophtalmologique d'Imagerie et de Laser   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Antivascular endothelial growth factor; Bevacizumab; Choroidal neovascularization; Myopia; Ranibizumab

Indexed keywords

BEVACIZUMAB; PLACEBO; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

CLINICAL TRIAL; DRUG SAFETY; FLUORESCENCE ANGIOGRAPHY; HUMAN; LASER COAGULATION; LOW DRUG DOSE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; OPTIMAL DRUG DOSE; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; HUMANS; MYOPIA, DEGENERATIVE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 70349122183     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b1bb1a     Document Type: Review

References (67)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103:1241-1244.
2. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981;91:177-183.
3. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schep-ens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
4. Miller DG, Singerman LJ. Natural history of choroidal neo-vascularization in high myopia. Curr Opin Ophthalmol 2001; 12:222-224.
5. Bottoni F, Tilanus M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int Ophthalmol 2001;24:249-255.
6. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002;109: 712-719.
7. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic cho-roidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110:1297-1305.
8. Ohno-Matsui K, Yoshida T. Myopic choroidal neovascular-ization: natural course and treatment. Curr Opin Ophthalmol 2004;15:197-202.
9. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-673.
10. Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 2005;89:1522-1528.
11. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 2008;53:121-138.
12. Mateo C, Moreno J, Rosales G, et al. Two-year results of macular translocation with scleral infolding in myopic choroi-dal neovascularisation. Semin Ophthalmol 2004;19:29-42.
13. Glacet-Bernard A, Benyelles N, Dumas S, et al. Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study. Am J Ophthalmol 2007;143:68-76.
14. Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Oph-thalmol 2000;118:344-350.
15. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001;85:1041-1043.
16. Essex RW, Tufail A, Bunce C, Aylward GW. Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br J Ophthal-mol 2007;91:649-654.
17. Kobayashi H, Kobayashi K. Radiotherapy for subfoveal neo-vascularisation associated with pathological myopia: a pilot study. Br J Ophthalmol 2000;84:761-766.
18. Costa RA, Calucci D, Teixeira LF, Cardillo JA, Bonomo PP. Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 2003;135:857-866. (Pubitemid 36677405)
19. Ozdek S, Hondur A, Gurelik G, Hasanreisoglu B. Transpupil-lary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int Ophthalmol 2005; 26:127-133.
20. Wu PC, Chen YJ, Chen CH, et al. Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neo-vascularization: one- and two-year follow up. Clin Experiment Ophthalmol 2008;36:443-448.
21. Degenring RF, Jonas JB. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neo-vascularization. Acta Ophthalmol Scand 2005;83:621.
22. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 2006;142:335-337.
23. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007;91: 174-179.
24. Soubrane G, Pison J, Bornert P, Perrenoud F, Coscas G. Résultats de la photocoagulation des néovaisseaux sous-réti-niens de la myopie forte. Bull Soc Ophtalmol Fr 1986;86:269-272.
25. Secrétan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7:307-316.
26. Brancato R, Pece A, Avanza P, Radrizzani E. Photocoagula-tion scar expansion after laser therapy for choroidal neovas-cularization in degenerative myopia. Retina 1990;10:239-243.
27. Pece A, Brancato R, Avanza P, Camesasca F, Galli L. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol 1994-1995; 18:339-344.
28. Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 2002;12:117-122.
29. Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK. Photodynamic therapy with verteporfin for subfoveal choroi-dal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 2004;88:1315-1319.
30. Schnurrbusch UE, Jochmann C, Wiedemann P, Wolf S. Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2005;243:829-833.
31. Pece A, Isola V, Vadala M, Matranga D. Photodynamic therapy with verteporfin for subfoveal choroidal neovasculariza-tion secondary to pathologic myopia: long-term study. Retina 2006;26:746-751.
32. Chen YS, Lin JY, Tseng SY, Yow SG, Hsu WJ, Tsai SC. Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up. Retina 2007;27:839-845.
33. Ruiz-Moreno JM, Amat P, Montero JA, Lugo F. Photody-namic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 2008;92: 792-794.
34. Cohen SY, Bulik A, Dubois L, Quentel G. Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am J Ophthalmol 2003;136:371-374.
35. Lam DS, Liu DT, Fan DS, Lai WW, So SF, Chan WM. Photodynamic therapy with verteporfin for juxtafoveal choroi-dal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Eye 2005;19:834-840.
36. Gibson J. Photodynamic therapy with verteporfin for juxtafo-veal choroidal neovascularization secondary to pathological myopia. Eye 2005;19:829-830.
37. Pece A, Vadalà M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovasculariza-tion in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007;143:449-454.
38. Virgili G, Varano M, Giacomelli G, et al. Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia. Am J Ophthalmol 2007;143:77-82.
39. Gelisken F, Inhoffen W, Hermann A, Grisanti S, Bartz-Schmidt KU. Verteporfin photodynamic therapy for extrafo-veal choroidal neovascularisation in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2004;242:926-930. (Pubitemid 39562327)
40. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
41. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
42. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005;25:119-134.
43. Lipski A, Bornfeld N, Jurklies B. Photodynamic therapy with verteporfin in paediatric and young adult patients: long-term treatment results of choroidal neovascularisations. Br J Oph-thalmol 2008;92:655-660.
44. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM Jr, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008;126:941-945.
45. Rosenfeld PJ. Intravitreal Avastin for choroidal neovasculari-sation in pathological myopia: the controversy continues. Br J Ophthalmol 2007;91:128-130.
46. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006;26:960-963. (Pubitemid 44547453)
47. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165. (Pubitemid 46202863)
48. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-160.
49. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevaci-zumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-2196.
50. Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-712.
51. Dithmar S, Schaal KB, Höh AE, Schmidt S, Schütt F. Intra-vitreal Bevacizumab bei choroidaler Neovaskularisation in-folge pathologischer Myopie. Ophthalmologe 2009;106:527-530.
52. Rensch F, Spandau UH, Schlichtenbrede F, et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008;39:182-185.
53. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147:84-93.
54. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-1123.
55. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008;92: 1035-1039.
56. Rhéaume MA, Sebag M. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Can J Ophthalmol 2008;43:576-580.
57. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
58. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Am-bresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:311-318.
59. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009; Jan 16 Epub of print.
60. Sayanagi K, Ikuno Y, Soga K, Wakabayashi T, Tano Y. Marginal cracks after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol (Copenh) 2008;85:50-54.
61. Neri P, Mariotti C, Mercanti L, Salvolini S, Giovannini A. Vitritis in the contralateral uninjected eye following intravitreal bevaci-zumab (Avastin). Int Ophthalmol 2008;28:425-427.
62. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intra-vitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
63. Baba T, Ohno-Matsui K, Yoshida T, et al. Optical coherence tomography of choroidal neovascularization in high myopia. Acta Ophthalmol Scand 2002;80:82-87.
64. Wong D, Li KK. Avastin in myopic choroidal neovasculari-sation: is age the limit? Br J Ophthalmol 2008;92:1011-1012.
65. Axer-Siegel R, Ehrlich R, Weinberger D, et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 2004;138:602-607.
66. Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal cho-roidal neovascularization in pathologic myopia. Am J Oph-thalmol 2004;138:434-438.
67. Parodi MB, Da Pozzo S, Ravalico G. Retinal pigment epithe-lium changes after photodynamic therapy for choroidal neo-vascularization in pathological myopia. Acta Ophthalmol Scand 2007;85:50-54.